AlphaStocks
5.6
Consider Buy

Krystal Biotech, Inc. (KRYS)

Health Care / Biotechnology

S&P SmallCap 600

$259.19

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 3 of 5 models — moderate confidence

#410out of 1127 in Health Care

Is Krystal Biotech, Inc. a Good Investment in 2026?

Krystal Biotech, Inc. (KRYS) scores 5.6 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Krystal Biotech, Inc. as Attractive (6/9). However, the Graham model rates it Caution — Significantly above fair value. Krystal Biotech, Inc. currently trades above its estimated fair value of $218, suggesting limited upside at current prices. Krystal Biotech, Inc. ranks #410 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E37.9ROE17.2Market Cap8B

Estimated Fair Value

$218.1019% above

Trading slightly above estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Krystal Biotech, Inc. (KRYS) a good investment?
Based on AlphaStocks' composite analysis, Krystal Biotech, Inc. (KRYS) scores 5.6 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading slightly above estimated fair value.
What is Krystal Biotech, Inc.'s Piotroski F-Score?
Krystal Biotech, Inc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is KRYS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $218, KRYS appears overvalued. The stock currently trades 19% above its estimated fair value. Trading slightly above estimated fair value.
How does KRYS compare to other Health Care stocks?
Krystal Biotech, Inc. ranks #410 out of 1127 stocks in the Health Care sector, placing it in the top 36% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about KRYS?
AlphaStocks evaluates KRYS using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 5.6/10.

Similar Stocks

PARRFTIAZN

Compare KRYS with

KRYS vs PARRKRYS vs FTIKRYS vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer